Business Wire

Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

Jaa

Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) who are ineligible for autologous stem cell transplant. This application represents the first chimeric antigen receptor (CAR) T-cell therapy submitted to the EMA. Axicabtagene ciloleucel is currently under review by the U.S. Food and Drug Administration (FDA), and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of November 29, 2017.

The MAA for axicabtagene ciloleucel is supported by data from the ZUMA-1 trial, which met the primary endpoint of objective response rate (ORR), with 82 percent (p < 0.0001) of patients achieving a response after a single infusion of axicabtagene ciloleucel. At a median follow-up of 8.7 months, 44 percent of patients were in ongoing response, which included 39 percent of patients in complete response (CR). The most common Grade 3 or higher adverse events included cytokine release syndrome and neurologic events, which were generally reversible.

“The MAA submission of axicabtagene ciloleucel marks an important global milestone in the development of engineered T cell therapy,” said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. “We are excited to work closely with the EMA, Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) to help bring this potentially transformative therapy to patients in the EU.”

Non-Hodgkin lymphoma (NHL) is a type of blood cancer that affects around 93,000 people in Europe every year.i DLBCL is one of the subtypes of NHL that is aggressive or fast growing.ii While many patients can achieve and maintain complete remission after initial treatment, patients who experience relapse or do not respond to initial treatment historically have poor outcomes. The company estimates that approximately 7,800 patients in the EU 5 alone may benefit from CAR-T therapy.

In May 2016, the CHMP and CAT granted access to its newly established Priority Medicines (PRIME) regulatory initiative for axicabtagene ciloleucel in the treatment of patients with refractory DLBCL. Access to the PRIME initiative is granted by the EMA to support the development and accelerate the review of new therapies to treat patients with a high unmet need.

About axicabtagene ciloleucel

Kite's lead product candidate, axicabtagene ciloleucel, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.

About Kite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of axicabtagene ciloleucel, and the ability to obtain EMA approval for axicabtagene ciloleucel. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

i Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer 2013;49:1374-1403.
ii Non-Hodgkin Lymphoma (NHL). “NHL Subtypes” Leukemia & Lymphoma Society. http://www.lls.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes [Last accessed July 20, 2017].

Contact information

Kite Contacts
Christine Cassiano
SVP, Corporate Communications & Investor Relations
ccassiano@kitepharma.com
Greg Mann
VP, Investor Relations
gmann@kitepharma.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Mobile Ticket Option Launches for Tampa Bay CityPASS17.10.2017 12:00Tiedote

City Pass, Inc., the company that specializes in packaging discounted admission to the most iconic attractions in 12 North American destinations, recently launched a mobile ticket option for its Tampa Bay CityPASS® program. Since 1997, CityPASS products have been designed to make travel easier and less expensive. And while the Tampa Bay CityPASS program will continue to excel at the latter—saving visitors 51 percent off combined admission to the included attractions—the new mobile ticket option dramatically enhances the convenience factor. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005538/en/ Busch Gardens Tampa Bay (Photo: SeaWorld Parks & Entertainment, Inc.) “We’re always looking for ways to improve the customer experience and make travel more convenient,” said CityPASS President a

Opus Trust Marketing Invests in Pitney Bowes’ Technology to Accelerate Growth17.10.2017 11:00Tiedote

Pitney Bowes Inc. (NYSE:PBI), a global technology company providing innovative products and solutions to power commerce, today announced that it has won a contract with Leicester-based Opus Trust Marketing. The contract will help Opus Trust accelerate growth and deliver its ambitious strategic development plans. Opus Trust specialises in multichannel communications, critical document printing and mailing for a diversity of high profile clients, including 20% of the FTSE 100. It is investing in Pitney Bowes’ Pulse™ inserting system as well as two of Pitney Bowes’ high-performance multi format inserters, Epic™. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005541/en/ The Pulse™ inserting system (Photo: Business Wire) Opus Trust is also investing its time in Pitney Bowes’ digital cus

NEC Europe Appoints Hironobu Kurosaki as President and CEO17.10.2017 11:00Tiedote

NEC Europe Ltd. today announced the appointment of Hironobu Kurosaki as President and CEO. In this role, Mr. Kurosaki will lead the growth of NEC Europe’s business for a broad range of customers spanning across its key business segments of Public Safety, Public IT services and Telecom Carrier Solutions in the EMEA region (Europe, the Middle East and Africa). Since joining NEC in 1983, Mr. Kurosaki has gained extensive international experience in the development of sales, marketing and strategy throughout the Americas and EMEA. In recent years, he has played a leading role in the development of NEC’s global business, where his experience as President of NEC Telecommunication and Information Technology Ltd. (Turkey), and contributions as General Manager of NEC’s Americas and EMEA Division have helped to deliver high-powered solutions and drive new growth in strategic ma

MagicStay, The Start-up of Short-Term Rental for Business, Affirms Its Ambitions at the Web Summit 201717.10.2017 11:00Tiedote

The French start-up MagicStay.com launched 3 years ago, now offers more than 130,000 apartments in 110 countries on its specialized platform for business travelers. As the only 100% B2B platform, MagicStay has developed many services adapted to the requirements of businesses, especially in terms of security and integration into their tools, which will be presented at the Web Summit in Lisbon from 6 to 9 November. For three years now, the start-up has been developing an exclusive technology that makes it possible to provide a global supply of short-term rentals in immediate reservations. These professionally managed accommodations meet corporate requirements: security, legislation compliance, and integration into booking tools used by corporate companies. "The Business Travel Market is very complex in terms of technology and actors, and is highly

Sigma Systems Appoints Vladimir Mitrasinovic as Senior Vice-President of Sales and Managing Director for EMEA and APAC17.10.2017 11:00Tiedote

Sigma Systems, the leader in catalog-driven software, has appointed Vladimir Mitrasinovic as Senior Vice-President of Sales and Managing Director for EMEA and APAC. Mr. Mitrasinovic was previously Head of the Cloud and Software as a Service business unit for Cerillion Technologies, and served as Executive Vice-President of Global Channels and Alliances at Acision (XURA). As Senior Vice President of Sales and Managing Director of EMEA and APAC, Vladimir will oversee all sales and business development efforts within the regions. “We are delighted to welcome Vladimir to the Sigma team,” said Simon Muderack, Sigma’s Executive Vice President and Chief Commercial Officer. “Vladimir’s background in high-growth corporate development in the technology sector and experience in sales and business expansion will be an excellent asset to Sigma as we continue to expand across EMEA and

REFLEX CES Partners with NOLAM EMBEDDED SYTEMS to Provide Integrated CANbus IP Core Solutions on FPGA COTS Boards17.10.2017 10:00Tiedote

NOLAM EMBEDDED SYSTEMS, manufacturer of semiconductor IP and board level products and systems for the Aerospace, Defense, telecom and industrial markets, today announced their partnership with REFLEX CES, a leading provider of complex, high-density FPGA-based boards. This partnership benefits customers by providing them a fully integrated solution based on REFLEX CES FPGA boards and NOLAM EMBEDDED SYSTEMS CANbus IP core and CANbus FMC module. «We are thrilled to collaborate with REFLEX CES to offer a fully integrated CANbus solution», stated Benjamin Nakache, Vice-President of Sales at Nolam Embedded Systems «By integrating our CANbus IP solution with our CANbus FMC to the REFLEX CES hardware, we bring a very easy-to use solution to CANbus users in the automotive industry.» One of the first outcomes of this collaborative venture is the release of an SDK, composed of REF

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme